



## Ragini Adams

Clinical Assistant Professor, Pediatrics - Hematology & Oncology

### CLINICAL OFFICES

- **Oncology**

1000 Welch Rd Ste 300

Palo Alto, CA 94304

Tel (650) 723-5535

Fax (650) 723-5231

### Bio

---

#### BIO

Ragini Adams, MD is a Clinical Assistant Professor in the Division of Pediatric Hematology, Oncology, Stem Cell Transplant and Regenerative Medicine at the Lucile Packard Children's Hospital, Stanford University School of Medicine. Dr. Adams obtained her BS in Biology at the Massachusetts Institute of Technology where she also completed her thesis in the field of Medical Anthropology. She then joined the Stanford University Cancer Center where she managed clinical trials related to the study of biomarkers in Diffuse Large B Cell Lymphoma. She then earned her MD from the East Tennessee State University Quillen College of Medicine. Dr. Adams completed a residency in Pediatrics at Georgetown University where her research focused on multidisciplinary therapies for retinoblastoma and hepatoblastoma. Currently, Dr. Adams is dedicated to the personal and comprehensive care of her pediatric hematology and oncology patients extending across a variety of diseases. Dr. Adams's present research in the Alizadeh Lab is focused on using circulating tumor DNA to genetically profile and monitor pediatric patients diagnosed with Hodgkin Lymphoma. In 2021, Dr. Adams completed her fellowship in Pediatric Hematology and Oncology at Stanford University. Dr. Adams is a board certified pediatrician and is also practicing in Pediatric Urgent Care.

#### CLINICAL FOCUS

- Pediatric Hodgkin Lymphoma
- Circulating Tumor DNA
- Pediatric Hematology-Oncology

#### ACADEMIC APPOINTMENTS

- Clinical Assistant Professor, Pediatrics - Hematology & Oncology

#### HONORS AND AWARDS

- Tashia and John Morgridge Endowed Postdoctoral Fellow, Stanford Maternal and Child Health Research Institute (MCHRI) (2019 - 2021)

#### PROFESSIONAL EDUCATION

- Fellowship: Stanford University Pediatric Hematology Oncology Fellowship (2021) CA
- Board Certification: Pediatrics, American Board of Pediatrics (2018)
- Residency: MedStar Georgetown University Pediatrics Program (2018) DC

- Medical Education: East Tennessee State University Medicine (2015) TN
- Board Certification, American Board of Pediatrics , General Pediatrics (2018)
- Residency, Georgetown University , Pediatrics (2018)
- MD, East Tennessee State University Quillen College of Medicine (2015)
- BS, Massachusetts Institute of Technology , Biology, Anthropology (2008)

## Research & Scholarship

---

### CURRENT RESEARCH AND SCHOLARLY INTERESTS

Circulating tumor DNA (ctDNA) is DNA that is released by tumor cells into the blood of the host; it is a fraction of all the cell free DNA (cfDNA) that is present. Because ctDNA contains the mutations of the original tumor, it is detectable using next generation sequencing and is an accurate surrogate measure of tumor burden. Therefore, ctDNA is an emerging biomarker in Hodgkin Lymphoma (HL) that is specific, quantifiable, and can be measured by noninvasive means. Using ctDNA to explore the genetic landscape of pediatric HL and monitor the response of these patients to therapy has never been done before and is my current focus of study.

## Publications

---

### PUBLICATIONS

- **Evans Syndrome**  
Shyam, R., Sakamoto, K.  
Medscape.  
2020
- **Pathophysiological significance and therapeutic targeting of germinal center kinase in diffuse large B-cell lymphoma.** *Blood*  
Matthews, J. M., Bhatt, S., Patricelli, M. P., Nomanbhoy, T. K., Jiang, X., Natkunam, Y., Gentles, A. J., Martinez, E., Zhu, D., Chapman, J. R., Cortizas, E., Shyam, R., Chinichian, et al  
2016; 128 (2): 239-248
- **The effect of iron- and light-limitation on phytoplankton communities of deep chlorophyll maxima of the western Pacific Ocean** *JOURNAL OF MARINE RESEARCH*  
Johnson, Z. I., Shyam, R., Ritchie, A. E., Mioni, C., Lance, V. P., Murray, J. W., Zinser, E. R.  
2010; 68 (2): 283–308
- **Lymphoma cell VEGFR2 expression detected by immunohistochemistry predicts poor overall survival in diffuse large B cell lymphoma treated with immunochemotherapy (R-CHOP)** *BRITISH JOURNAL OF HAEMATOLOGY*  
Gratzinger, D., Advani, R., Zhao, S., Talreja, N., Tibshirani, R. J., Shyam, R., Horning, S., Sehn, L. H., Farinha, P., Briones, J., Lossos, I. S., Gascoyne, R. D., Natkunam, et al  
2010; 148 (2): 235-244